TNF and cytomegalovirus infection: Conversely, monoclonal antibodies against TNF-α such as infliximab or adalimumab do not increase the risk of CMV reactivation [44,62,66,67] and tissue CMV infection is not associated with clinical resistance to these biotherapies [114].